ArticleJournal of viral hepatitis2022
Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
Article in Journal of viral hepatitis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- HBV RNA at 6 months after nucleos(t)ide analogues treatment can predict antiviral efficacy in chronic hepatitis B patients.BMC gastroenterology · 2026Article
- Association of baseline HBcAg and HBV DNA with persistent detectability of HBV RNA during NA therapy.PloS one · 2026Article
- The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatment.Frontiers in cellular and infection microbiology · 2026Review
- Plasma gamma-glutamylglycine predicts the seroconversion of hepatitis B e antigen in patients with chronic hepatitis B.Frontiers in immunology · 2026Article
- Development of an over-gap droplet digital PCR assay and evaluation of serum HBcrAg/qAnti-HBc as noninvasive markers for intrahepatic replication-competent HBV DNA in chronic hepatitis B patients with HBsAg loss.Emerging microbes & infections · 2025Article
- Factors Positively Correlated with Hepatitis B Surface Antigen Seroconversion in Chronic Hepatitis B.Journal of personalized medicine · 2024Article
- Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy.Infectious agents and cancer · 2022Article
- Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.Journal of viral hepatitis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the predictive value of serum HBV DNA, HBV RNA, HBcrAg, HBsAg, intrahepatic HBV DNA and cccDNA for HBeAg clearance and seroconversion during long-term treatment with nucleos(t)ide analogues (NAs) in patients with chronic hepatitis B (CHB). A single centre, prospective cohort of CHB patients was used for this study. Serum HBV RNA levels were retrospectively measured at baseline, 6, 12, 24, 36, 48, 60, 72 and 84 months post-NAs treatment. Serum HBsAg and HBcrAg levels were quantified at baseline, month 6, 60 and 72. Histological samples from liver biopsy at baseline and month 60 were analysed for intrahepatic HBV DNA and cccDNA. Eighty-three HBeAg-positive patients were enrolled with a median follow-up time of 108 months (range 18-138 months). Of them, 53 (63.86%) patients achieved HBeAg clearance, and 37 (44.58%) achieved HBeAg seroconversion. Cox multivariate analysis showed that only baseline HBV RNA was independently associated with HBeAg clearance and seroconversion (<5.45 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.